ARGX (argenx SE) Cyclically Adjusted Revenue per Share: $18.74 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARGX argenx SE ARGX
78 GF Score
Price $860.94
GF Value $1,451.23
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Cyclically Adjusted Revenue per Share?

argenx SE ARGX +0.30% 78 Cyclically Adjusted Revenue per Share is $18.74 as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 78/100 and a GF Value™ of $1,451.23 (Significantly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

argenx SE's adjusted revenue per share for the three months ended in Mar. 2026 was $19.561. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $18.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, argenx SE's average Cyclically Adjusted Revenue Growth Rate was 71.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 77.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of argenx SE was 77.80% per year. The lowest was 77.80% per year. And the median was 77.80% per year.

As of today (2026-07-19), argenx SE's current stock price is $860.94. argenx SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $18.74. argenx SE's Cyclically Adjusted PS Ratio of today is 45.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of argenx SE was 171.16. The lowest was 40.63. And the median was 77.30.


argenx SE  (NAS:ARGX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

argenx SE's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=860.94/18.74
=45.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of argenx SE was 171.16. The lowest was 40.63. And the median was 77.30.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


argenx SE Cyclically Adjusted Revenue per Share Related Terms


argenx SE Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for argenx SE's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Cyclically Adjusted Revenue per Share Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.71 4.94 8.25 16.42

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.19 12.51 14.73 16.42 18.74

ARGX vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, argenx SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where argenx SE's Cyclically Adjusted PS Ratio falls into.


ARGX
78GF Score
argenx SE ARGX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, argenx SE's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.561/136.9100*136.9100
=19.561

Current CPI (Mar. 2026) = 136.9100.

argenx SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.120 99.730 0.165
201603 0.159 100.310 0.217
201606 0.189 100.260 0.258
201609 0.275 100.570 0.374
201612 0.183 100.710 0.249
201703 0.274 101.440 0.370
201706 0.691 101.370 0.933
201709 0.286 102.030 0.384
201712 0.321 101.970 0.431
201803 0.212 102.470 0.283
201806 0.426 103.100 0.566
201809 0.068 103.950 0.090
201812 0.040 103.970 0.053
201903 1.031 105.370 1.340
201906 0.225 105.840 0.291
201909 0.202 106.700 0.259
201912 0.521 106.800 0.668
202006 0.000 107.510 0.000
202012 0.000 107.850 0.000
202103 3.166 108.870 3.981
202106 5.381 109.670 6.718
202109 0.017 110.790 0.021
202112 0.505 114.010 0.606
202203 0.450 119.460 0.516
202206 1.372 119.050 1.578
202209 2.499 126.890 2.696
202212 3.145 124.940 3.446
202303 3.945 124.720 4.331
202306 4.846 125.830 5.273
202309 5.673 127.160 6.108
202312 6.879 126.450 7.448
202403 6.761 128.580 7.199
202406 7.983 129.910 8.413
202409 8.730 131.610 9.082
202412 11.294 131.630 11.747
202503 12.031 133.330 12.354
202506 14.452 133.960 14.770
202509 16.962 135.920 17.086
202512 19.430 135.270 19.666
202603 19.561 136.910 19.561

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $18.74 mean?
argenx SE (ARGX) has a Cyclically Adjusted Revenue per Share of $18.74 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on argenx SE and its competitors.
Is argenx SE's Cyclically Adjusted Revenue per Share too high?
argenx SE's current Cyclically Adjusted Revenue per Share is $18.74. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
argenx SE's Cyclically Adjusted Revenue per Share of $18.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on argenx SE and its competitors. argenx SE's current Cyclically Adjusted Revenue per Share is $18.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,451.23, compared to a current price of $860.94 — trading 40.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $18.74. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For argenx SE (ARGX), the current Cyclically Adjusted Revenue per Share is $18.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (ARGX) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of $860.94 is trading 40.7% below its estimated GF Value™ of $1,451.23. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for ARGX:

  • Cyclically Adjusted Revenue per Share: $18.74
  • GF Value™: $1,451.23 vs. price of $860.94 (40.7% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score

Get the complete analysis for ARGX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$860.94
Price
$1,451.23
GF Value